SPSC · Investment summary · as of 29 July 2026
Priced slightly ahead of what the business has demonstrated
Business type: mature and structurally stable
At $70.02, SPSC requires a 8% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 6%.
The value rests on an exit multiple of 22.6x and a terminal operating margin of 15%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause: SPSC has been buying revenue growth at roughly 5x sales to offset an organic rate that is now ~6%, and the acquisition engine has stopped covering the gap.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Not determined — the operating driver is not stated in one place |
| What do we forecast? | Revenue growth of 6% demonstrated; a terminal operating margin of 15%; an exit multiple of 22.6x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -2.3 percentage points. |
| What is it worth? | Not determined — Mechanical carry at an unchanged 3.17x is $75.2 (+7.4%) and is explicitly not a target. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 29 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| Q2-2026 | Q2-2026 revenue above ~$205m (against guidance of $194.5–196.5m).… | Neither leg of the condition opposite is met at this date | Q2-2026 revenue above ~$205m (against guidance of $194.5–196.5m). That would be >+9% YoY and would break the… |
| FY2026 | FY2026 revenue guidance raised above 8% at any point in the year. The… | FY2026 revenue guidance raised at or below 8% at any point in the year. The current $796–802m implies 6–7%. | FY2026 revenue guidance raised above 8% at any point in the year. The current $796–802m implies 6–7%. |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Named cause: SPSC has been buying revenue growth at roughly 5x sales to offset an organic rate that is now ~6%, and the acquisition engine has stopped covering the gap. The mechanism is arithmetic, not narrative. Reported growth = organic + acquired. Organic is ~6% and decelerating with retail-supplier spend. Acquired growth requires ~$210m of consideration per deal to add ~$40m of revenue (Carbon6), i.e. ~5.0x revenue, funded from a $154m cash balance and share issuance from treasury. Two deals in fourteen months consumed $424m and produced $270m of goodwill. When the deals anniversary — whic
Falsifiable and fundamental — not one of them is a price condition.
Not determined — no upside discipline is stated, so there is no rule for how this position ends in a favourable outcome
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Not determined | Can the intended position be built and exited in the right vehicle? Not established on the evidence on file. |
| Downside | Met | Named cause: SPSC has been buying revenue growth at roughly 5x sales to offset an organic rate that is now ~6%, and the acquisition engine has stopped covering the gap. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -2.3 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $60.61, which forces an immediate review.